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It  now  appears  that  slow-reacting  substances  of anaphylaxis (SRS-A) a and 
histamine are the most important mediators of bronchoconstriction in asthmatic 
symptoms (1-3). SRS-A have recently been shown to be LTC4, LTD4, and LTE4 
derived from arachidonic acid via the 5-1ipoxygenase pathway (4,  5).  Another 
important metabolite of this pathway is LTB4 (6,  7).  Studies on the biological 
activities of these metabolites suggested their involvement in several allergic and 
inflammatory diseases. The spasmogenic activity of LTC4 and LTD4 on guinea 
pig lung parenchymal strips is ~200-20,000-fold greater than that of histamine; 
on guinea pig trachea, they are 30 and 100 times, respectively, more potent than 
histamine (8). Furthermore, LTC4 and LTD4 have been shown to cause contrac- 
tion of human bronchi in vitro and in vivo (9-13). In addition, LTC4 and LTD4 
have been shown to increase mucous secretion in canine trachea (14) and human 
bronchia  mucosa  (15,  16).  LTB4 was  shown  to  be  a  potent  chemotactic and 
degranulating substance towards polymorphonuclear leukocytes studied in vivo 
and in vitro (17,  18). Synthesis of leukotrienes has been reported in several cells 
and tissues including human and guinea pig lung tissues (19).  In human lung 
tissue, the major source of ieukotrienes has been suggested to be the mast cells 
and the macrophages (20,  21).  Nevertheless, a  number of other cell types are 
located  in  either  bronchioli  or  lung  parenchyma,  and  their  role  in  allergic 
symptoms is not known. Therefore, it is important to investigate the release of 
mediators of allergic reaction in both tissues to obtain a better understanding of 
the role of these mediators in allergic reactions in vivo. This investigation was 
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designed to provide a  comprehensive study of the quantitative nature and  the 
time course relationships between  the release of 5-1ipoxygenase metabolites of 
arachidonic acid and of histamine in both human lung parenchyma and bronchi 
after immunologic or nonimmunologic challenge.  In  addition,  the  action  of a 
widely used antiallergic drug (sodium cromoglycate) on the release of histamine 
and leukotrienes was investigated and compared with the actions of a  5-1ipoxy- 
genase  inhibitor  (nordihydroguaiaretic  acid  [NDGA])  and  a  cyclooxygenase 
inhibitor (aspirin) in both allergen- and ionophore-stimulated human lung paren- 
chyma. 
Materials and Methods 
Materials.  High performance liquid chromatography (HPLC) grade organic solvents 
were purchased from Anachemia Chemical Co. (Montreal) and glass-distilled  before use. 
[1-14C]Arachidonic acid (50 mCi/mmol), [3H]LTB4 (100 Ci/mmol), [SH]LTC4 (20-60 Ci/ 
mmol), and S-adenosyi-L-[methyl-SH]methionine  (75-85 Ci/mmol) were purchased from 
Amersham Corp.  (Oakville, Ontario).  Histamine was  purchased from Sigma Chemical 
Company (St.  Louis, MO), arachidonic acid from NuChek Prep Inc. (Elysian,  MN), and 
ionophore A23187  from Calbiochem-Behring Corp. (San  Diego, CA).  FPL55712 was 
obtained from Fison  Pharmaceutical  Ltd.  (Loughborough, England).  Synthetic leuko- 
trienes  were  kindly  provided  by  Dr.  Rokach  (Merck  Frosst  Laboratory,  Montreal). 
Histamine N-methyl-transferase was purified from rat kidneys as reported (22). Timothy 
allergen  was  obtained  from  Allergopharma Joachim  (Ganzer  KG  D-2057;  Reinbek, 
Federal Republic of Germany) and purified by dialysis before use. 
Preparation  of Human  Lung Parenchymal  and Bronchial  Fragments.  Lung specimens 
were  obtained  from  patients  undergoing  surgery  for  lung  carcinoma.  Histologically 
normal tissue was used for this investigation. The parenchyma was separated from bronchi 
by surgical blades. Both the parenchyma and bronchioli (2-5 mm diam) were chopped 
finely into fragments of ~2 mm  2. The tissues were then washed five times with phosphate- 
buffered saline (PBS) and kept on ice until use. 
Passive Sensitization  of Parenchyma and Bronchi.  Fragments of parenchyma or bronchi 
were incubated with serum from timothy-positive allergic patients (radioallergosorbent 
test [RAST], 30-40%) for 3 h at 37°C (1 ml of serum for 2 g of tissue wet weight and 5 
ml of PBS) under an atmosphere of 95%  02/5%  CO~ with constant shaking.  Control 
tissues  were incubated in the same manner with serum from timothy-negative subjects 
(demonstrating a negative skin test). 
Incubation  and Extraction Procedures.  Passively sensitized or nonsensitized tissue frag- 
ments were washed five times to remove serum and incubated either with 0.5 tag/ml of 
timothy allergen (1 g tissue wet weight/10 ml of PBS) or ionophore A23187 (4 taM final 
concentration) for different periods of time.  In some cases,  the tissue  fragments were 
incubated with both ionophore A23187 (4 taM final concentration) and arachidonic acid 
(30 tam final concentration). The incubations were ended by addition of 1 vol methanol 
containing prostaglandin B2 (PGB2) (150 rig) as an  internal standard.  The incubation 
media were centrifuged (3000 g, 30 rain) and the supernatant fluids were concentrated 
in vacuo. The residues were resuspended in 5 ml of 20% methanol and acidified to pH 
3. The samples were then passed through a cartridge of octadecylsilyl silica (SEP-PAK, 
C 18 cartridge; Waters Associates, Millipore Corp., Milford, MA). The extraction proce- 
dure was as reported (23) except that the metabolites of arachidonic acid were eluted with 
10 ml of 90% methanol. Using this method of extraction, the recovery of [~H]LTB4 (1.7 
×  105 dpm; mass, 34 ng) and of [SH]LTC4 (1.6 X 105 dpm; mass, 39 ng) were 84 +  2.6% 
and 73 +_ 3.1%, respectively (mean + SEM; n -- 5). 
Reverse Phase HPLC.  Chromatography was  performed using a  Cls-Radial  Pak car- 
tridge (100 X 8 mm inside diameter, 10 #m particle size; Waters Associates)  as reported 
(24), with a  modified gradient.  The metabolites of arachidonic acid were detected by 
ultraviolet spectrophotometry at 280 and 229 nm and quantitated by comparing the areas 1906  LEUKOTRIENES  AND  HISTAMINE  IN  HUMAN  LUNG 
of their peaks with that of the internal standard (PGB2) and correcting for differences in 
molar extinction coefficients and attenuation settings (25).  For further confirmation of 
the identity of leukotrienes, their biological activities were tested on contractions of guinea 
pig parenchymal strips or ileum and by the incorporation of z4C from [124C]arachidonic 
acid. Further identification of hydroxy-eicosatetraenoic  acid (Hete) and LTB4 were carried 
out by gas chromatography-mass spectrometry (GC-MS) as reported (26). 
Bioassay.  The HPLC fractions corresponding to LTB4, LTC4, and LTD4 were col- 
lected and evaporated to dryness in vacuo. The residues were collected in 250 #l of PBS 
containing  1%  ethanol.  Various  fractions of these  samples  were  added  to  10  ml  of 
oxygenated Krebs or Tyrode's buffer in an organ bath containing a suspended guinea pig 
lung parenchymal strip or ileum, as reported (27).  The contraction of organs by leuko- 
trienes was detected isometrically by a force displacement transducer and registered on a 
physiograph (desk model DMP-4A; Narco Bio-Systems,  Inc., Houston, TX). For further 
confirmation of the contractions induced by the  HPLC-eluted materials,  the synthetic 
leukotrienes were used as references. 
Histamine Assay.  Evaluation of the amount of histamine in the incubations was carried 
out using a radioenzymatic assay as reported (22).  Briefly, 25/~1 of sample was added to 
glass tubes containing 25 tsl of 0.5 M phosphate buffer, pH 7.8. A further 25 #1 of 0.5 M 
phosphate buffer, pH 7.8, containing S-adenosyl-L-[methyl-3H]methionine  (1.25 #Ci total) 
and 6 ttg of histamine N-methyl-transferase was added to each tube.  This mixture was 
incubated on ice for 1 h and the reaction was stopped by the addition of 1 vol of potassium 
borate (pH  11). After two organic solvent extractions,  125 #1 of the extracted solution 
was counted in a/3 liquid scintillation spectrometer and the amount of histamine in each 
sample  was  determined  by comparison  with  a  standard  curve obtained  from  known 
amounts of histamine. 
Results are expressed as mean -+ SEM. The statistical significance of differences between 
control and stimulated samples was determined using Student's t test. 
Results 
As shown in  Fig.  1 A,  unstimulated  human  lung parenchyma did not contain 
any significant amount of lipoxygenase metabolites.  However, when fragments 
of human lung parenchyma were stimulated with ionophore A23187 and arach- 
idonic  acid,  a  number  of lipoxygenase  metabolites  of arachidonic  acid  were 
detected (Fig.  1 B). Their identities were further confirmed by incorporation of 
14C from [1-14C]arachidonic acid.  Several unknown  peaks are also seen on  the 
chromatogram that did not correspond to any known metabolite of arachidonic 
acid.  The peak absorbance at  280 and  229 nm with the retention time of ~51 
min corresponded to the ionophore A23187.  When  fragments of human  lung 
parenchyma were stimulated with ionophore A23187 alone, w-COOH-LTB4, w- 
OH-LTB4, LTB4, 5-Hete, LTC4, LTE4, and LTD4 were detected in incubation 
media. Small amounts of 12-Hete and  15-Hete were occasionally detected (Fig. 
1 C).  Similarly, when fragments of passively sensitized human lung parenchyma 
were challenged with timothy allergen,  LTB4, LTC4, LTD4, LTE4, and 5-Hete 
were  the  major  metabolites  detected  but  in  amounts  less  than  the  amounts 
detected after ionophore stimulation (Fig.  1 D). To further confirm the presence 
of LTB4, LTC4, and LTD4, we tested the biological activity of the HPLC-eluted 
materials  corresponding  to  each  leukotriene on  the  contraction  of guinea  pig 
lung parenchymal strips and ileum. All three leukotrienes induced the contrac- 
tion  of  guinea  pig  lung  parenchymal  strips  comparable  to  that  induced  by 
standards (data not shown).  LTD4 induced contraction of both guinea pig lung 
parenchymal strips and of ileum, and its contractile activity was diminished when SALAR1  ET  AL.  1907 
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FIGURE  1.  HPLC chromatograms obtained from analysis of incubation media of human lung 
parenchymal fragments (1  g, wet weight in 10 ml of PBS) without stimulation (A), stimulated 
with ionophone A23187 and in the presence of arachidonic acid (B), stimulated with ionophone 
A23187 alone (C), or challenged with timothy allergen (D) for 15 min at 37 °C. The incubation 
was terminated with an equal volume of methanol containing 150  ng of PGB2. The traces 
show the UV absorbance at 280 and 229 nm. The attenuation setting of UV spectrophotom- 
eters were 0.02 and 0.05 OD, respectively. HPLC analysis showed peaks corresponding to 60- 
COOH-LTB4 (l), ~0-OH-LTB4 (II), PGB2 (S), LTB4 (lii), HHT (IV),  15-HETE (V),  12-HETE 
(VI), 5-HETE (VII), LTC4 (VIII), LTE4 (IX), and LTD4 (X). Open arrow at 56.5 rain indicates 
the 229 nm baseline shift. 
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FIGURE 2.  Time  course of LTB4 (1-1), LTC4  (I),  LTD4  (A),  and  LTE4  (O)  formation by 
human lung parenchymal fragments, stimulated with ionophore A23187. Mean _+ SEM, n  = 
12. (B) Time course of histamine release by human lung parenchymal fragments stimulated 
with ionophore A23187 (Q) and control (©). n =  7. 
the tissue was pretreated with 1 #M of FPL55712. LTC4 also induced contraction 
of guinea pig lung parenchymal strips and a  long-lasting contraction (> 15 min) 
of ileum (data not shown). LTB4 was less potent (>50 ng) in inducing contraction 
of guinea pig lung parenchymal strips, and failed to contract guinea pig ileum 
(data not shown). 
Time  Course  of Leukotrienes  and  Histamine  Release  by  Human  Lung  Paren- 
chyma.  Fig. 2A shows the release of LTB4, LTC4, LTD4, and LTE4 by 1 g (wet 
weight)  of lung  parenchyma  stimulated  with  ionophore  A23187.  LTC4  was 
released rapidly, reaching a  maximum after 5  min  of stimulation  (83  _  22.2 
pmol/g tissue, wet weight), and then decreased. The release of LTB4 and LTD4 
was, however, maximum after 15 rain (438 +  66.6 and 206 4- 68 pmol/g tissue, 1908  LEUKOTRIENES  AND  HISTAMINE  IN  HUMAN  LUNG 
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FmtJRE  3.  (A) Time course of" LTB4 (I-l), LTC4 (.), LTD4 (A), and LTE4 (O) formation by 
passively sensitized human lung parenchymal fragments challenged by timothy allergen, n = 
16.  (B) Time course of histamine release by passively sensitized human lung parenchymal 
fragments incubated with timothy allergen (O), without allergen (O). n = 9. 
respectively),  followed also by a  decrease.  The  formation  of w-OH-LTB4,  w- 
COOH-LTB4, and  LTE4 continued  to increase through  30 min of incubation. 
The presence of these  three  metabolites was further  confirmed  by ultraviolet 
(UV) scanning  and  bioassay on  guinea  pig  lung  parenchymal  strips  (data  not 
shown).  In  addition  to  releasing  leukotrienes,  human  lung  parenchyma  also 
released histamine  upon ionophore stimulation  (Fig.  2B). The release of hista- 
mine reached a maximum after ~5 rain (5.2 +  0.95 nmoi/g tissue wet weight). 
A  similar  pattern  of leukotriene  and  histamine  release  from  allergen-chal- 
lenged  human  lung  parenchyma  was  observed.  As  Fig.  3A  shows,  LTC4  was 
rapidly formed, reaching a maximum after 5 min (25 +  7.1 pmol/g tissue), after 
which its concentration  decreased.  In contrast,  maximum  release of LTB4 and 
LTD4 occurred  after  15  min  of challenge  (92.8  +  21  and  67.8  +  14 pmol/g 
tissue, respectively) while the amount of LTE4 continued to increase through 30 
min of incubation.  The presence of w-OH-LTB4 and 0~-COOH-LTB4 could not 
be ascertained,  since the amount of LTB4 formed after allergen challenge was 
two- to fivefold less than the amount formed by ionophore stimulation.  Human 
lung parenchyma  also rapidly released histamine  upon allergen  challenge (Fig. 
3B). However, in contrast  to the action of ionophore,  the release of histamine 
upon allergen  challenge continued to increase up to  15 min (275 ±  70 nmol/g 
tissue). 
Generation  of Lipoxygenase Metabolites  of Arachidonic  Acid  by  Human  Lung 
Bronchi.  Fragments  of human  lung bronchi (1  g, wet weight) were stimulated 
with ionophore A23 187 (4 #M) and arachidonic acid (30 gM). Analysis of the 15 
rain  incubation  media  by reverse  phase  HPLC demonstrated  the  presence  of 
LTB4,  LTD4, and  LTE4 as well as  15-Hete,  12-Hete and  5-Hete (217  +  65.6, 
61  +  22,  133  +  53.7,  230  ±  76.5,  200  ±  48,  and  350  ±  71  pmol/g  tissue, 
respectively;  n  =  5).  However,  when  fragments  of human  lung  bronchi  were 
stimulated with ionophore alone, LTB4, LTD4, LYE4,  12-Hete, and 5-Hete, but 
not  15-Hete, were detected (data not shown). The amounts of leukotrienes and 
Hetes released by ionophore  stimulation  were constantly  two- to fourfold less 
than the amounts formed upon stimulation with ionophore and arachidonic acid. 
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FIGURE 4.  (A) Time course of LTB4 ([-'1), LTD4 (A), and LTE4 (O) formation by human lung 
bronchial fragments stimulated with ionophore A23187. n =  7. (B) Time course of LTB4 (I--1), 
LTD4 (A), and  LTE4 (O) formation in passively sensitized human  lung bronchial fragments 
challenged with timothy allergen, n =  9. 
from timothy-positive allergic patients and then challenged with timothy allergen, 
LTB4, LTD4, and LTE4 were detected in amounts two- to fivefold less than the 
amounts formed by the ionophore-stimulated tissues (data not shown). Further- 
more, no Hetes were detectable (below the limit of detection). 
Time  Course  of Leukotriene  and  Histamine  Release  by  Human  Lung  Bron- 
chi.  When  human  lung  bronchi  were  stimulated  with  ionophore  A23187, 
maximum release of LTB4 and LTD4 was observed after 15 min (100 +  13 and 
47  +  10.6 pmol/g tissue, wet weight, respectively). However, the formation of 
LTE4 continued to increase through 30 min (Fig. 4A). LTC4, c0-OH-LTB4,  and 
co-COOH-LTB4 were not detected in any appreciable quantity. A similar profile 
of leukotriene release also was observed from passively sensitized human lung 
bronchi challenged with timothy allergen (Fig.  4B).  However, the amounts of 
leukotrienes  formed  in  bronchi  upon  allergen  challenge  were  less  than  the 
amounts  observed  after  ionophore  stimulation.  Furthermore,  the  maximum 
release of all the leukotrienes upon allergen challenge occurred after 30 min of 
incubation  (LTB4,  48  +  10.3;  LTD4,  27  +  9.7;  and LTE4,  36  +  8.2  pmol/g 
tissue, wet weight). Human lung bronchi also rapidly released histamine upon 
both  ionophore  stimulation  and  allergen  challenge  (Fig.  5).  The  release  of 
histamine upon ionophore stimulation was greater than the release induced by 
allergen  challenge and,  whereas  release  after  ionophore  stimulation  reached 
completion after ~5 min (3.15 +  0.9 nmol/g tissue), release induced by antigen 
challenge was not complete until 15 min (2.25 -+ 0.65 nmol/g tissue, wet weight). 
In addition, a small amount of histamine was constantly released from the control 
incubations of both parenchymal and bronchial fragments, probably due to the 
manipulation of the tissues. 
Effects of NDGA, Aspirin, and Sodium Cromoglycate on the Release of Leukotrienes 
and Histamine in Human Lung Parenchyma.  The action of NDGA, aspirin, and 
sodium cromoglycate on  the release of ieukotrienes and histamine by human 
lung  parenchyma  upon  challenge  with  ionophore  or  allergen  were  studied. 
NDGA inhibited (ID50, 2  ×  10 -6 M) both the ionophore-and allergen-induced 
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FIGURE  5.  Time course of histamine release in human lung bronchial fragments control (0), 
challenged with timothy allergen (I) or stimulated with ionophore A23187 (A). n  =  5. 
release of ieukotrienes. Sodium cromoglycate (10  -4 M) did not affect the release 
of leukotriene from tissue stimulated  with  ionophore,  but it slightly decreased 
the allergen-mediated release of leukotrienes (LTB4, 25 +  5%; LTC4, 50 +  9%; 
LTD4,  32 +  8.3%; and  LTE4,  33 _+ 7.5%;  n  --  14, P  <  0.05; data not shown). 
The  release  of histamine  by  human  lung  parenchyma  after  challenge  with 
allergen or ionophore was not affected by the action of either NDGA or aspirin. 
Allergen-mediated, but not ionophore-mediated, release of histamine by human 
lung  parenchyma  was also decreased (50  +  6%,  n  -  14, P  <  0.05),  when  the 
tissue was treated with  10 -4 M of sodium cromoglycate (data not shown). 
Discussion 
The present data indicate that human  lung parenchyma and bronchi  release 
histamine  and  products  of  the  5-1ipoxygenase  pathway  of  arachidonic  acid 
metabolism.  Among  the  5-1ipoxygenase  products,  the  SRS-A  family  (LTC4, 
LTD4,  and  LTE4)  are  the  predominant  products.  However,  an  appreciable 
amount of LTB4 also is released.  Previous investigations (28, 29) indicated that 
human lung parenchyma does not release LTB4 in an IgE-dependent mechanism, 
whereas LTB4 was shown to be released upon ionophore stimulation. In contrast, 
our results show that  both human  lung parenchyma and bronchi release  LTB4 
through  both  IgE-dependent  and  ionophore-mediated  mechanisms.  The  pres- 
ence of LTB4 was clearly defined not only by HPLC but also by bioassay and 
GC-MS. LTB4 has several important biological activities: it is a potent chemotactic 
and chemokinetic for human neutrophils with an activity comparable to that of 
fmet-leu-phe,  on a  molar basis, and it is an aggregatory substance (18,  30, 31). 
In addition to these pro-inflammatory actions, LTB4 causes contraction of lung 
parenchymal strips at concentrations  lower than  does histamine  (32). Thus,  the 
release of LTB4 by lung parenchyma and bronchi may be an important causative 
factor in the inflammation  of airway systems and may, in addition,  cause bron- 
chospasm. Another important aspect of this study is the finding that human lung 
parenchyma has the capacity to metabolize LTB4 into w-OH-LTB4 and w-COOH- SALARI  ET  AL.  1911 
LTB4. This demonstration  was clearly defined, using HPLC, bioassay, and GC- 
MS. Although 0>OH-LTB4 has been shown to be less chemotactic and aggrega- 
tory than  LTB4 (33-35), it is nevertheless as active as LTB4 in contracting lung 
parenchymal strips (32, 35). 
Other leukotrienes that were released by lung tissues were LTC4, LTD4, and 
LTE4. LTC4 and LTD4 have been shown (36) to be more potent than histamine 
in causing constriction of the airway system, particularly the peripheral airways. 
In addition,  they contract guinea pig trachea and human  bronchi and,  in both 
cases,  are  much  more active  than  histamine  (10,  37).  These  two leukotrienes 
were also found to induce mucous secretion in human bronchi (15). 
We have observed that human lung parenchyma releases significant amounts 
of 15-Hete,  12-Hete and  5-Hete. Our results confirm previous findings on the 
formation of Hetes by human lung tissues (28). However, in contrast to a previous 
report  (28),  we  noticed  that  5-Hete  and  not  I5-Hete  was  the  major  mono- 
hydroxy  acid.  These  differences  might  be  due  to  the  amount  of exogenous 
arachidonic acid added to the incubation medium or due to the time of incuba- 
tion.  Although  the  complete  biological activities of these  mono-hydroxy acids 
are unknown, 5-Hete and  12-Hete were shown to increase the anti-IgE-induced 
histamine  release from rat  mast cells (38) and  from human basophils (39, 40). 
Furthermore  15-Hete was shown to inhibit  5-1ipoxygenase activities in human 
PMNL (41). 
An  additional  novel  finding  of this  investigation  is  the  demonstration  that 
human bronchi also release appreciable amounts of biologically active 5-1ipoxy- 
genase metabolites of arachidonic acid. However, the amount of 5-1ipoxygenase 
products (i.e.,  LTB4,  LTD4,  and  LTE4)  formed by bronchi  was less th~n  that 
formed by parenchyma. In contrast to lung parenchyma,  LTC4 was not measur- 
able in human lung bronchi, but this finding does not reflect an absence of LTC4 
synthesis by bronchi, since its metabolites (i.e., LTD4 and LTE4) were constar.tly 
detected. Neither ~0-OH-LTB4 nor ~0-COOH-LTB4 was detected. 
The efficiency of sodium cromoglycate has been demonstrated with regard to 
the inhibition  of immediate  and  late asthmatic  responses, after antigenic  chal- 
lenges, and of exercise-induced asthma  (42, 43). Our results show that  sodium 
cromoglycate  does  not  significantly  inhibit  either  the  leukotriene  release  or 
histamine  release  by lung  tissues.  Only  at  a  high  concentration  (10 -4  M) was 
sodium chromoglycate able to reduce the release of leukotrienes and histamine, 
but even so it did not completely block this  release.  This  partial  inhibition  by 
sodium cromoglycate might be due to its action as a calcium antagonist (44, 45). 
Our studies with  aspirin  showed that  this  drug  neither  stimulates nor inhibits 
leukotriene formation or histamine release by lung tissues. These results do not 
support the hypothesis that allergy to aspirin  stems from an increase of lipoxy- 
genase  metabolites caused by aspirin-induced  inhibition  of the  cyclooxygenase 
pathway. However, we occasionally observed a slight, but not significant, decrease 
in the release of histamine  from parenchyma treated with  10  -4 M aspirip.  The 
lipoxygenase inhibitor (NDGA) was shown to be the only inhibitor of leukotriene 
formation in lung tissues, indicating that a potent lipoxygenase inhibitor should 
be  the  most  suitable  drug  in  the  treatment  of leukotriene-mediated  allergic 
reactions. 1912  LEUKOTRIENES  AND  HISTAMINE  IN  HUMAN  LUNG 
In  conclusion,  asthma  is  a  complex  disease  resulting  in  airway  narrowing 
because of combinations of airway muscle constriction, edema of the bronchial 
mucosa, mucosal infiltration with inflammatory cells, and excess mucous secre- 
tion  (46).  Leukotrienes and histamine are able to provoke these symptoms in 
vivo and  in  vitro.  Our  study shows  that  both  lung parenchyma and  bronchi 
release significant amounts of histamine and leukotrienes, suggesting that they 
are involved in human pulmonary allergic symptoms. 
Summary 
Fragments  of human  lung  parenchyma  or  bronchi  were  studied  by  high 
performance liquid  chromatography, gas chromatography-mass spectrometry, 
and bioassay for the biosynthesis of 5-1ipoxygenase metabolites of arachidonic 
acid, and by radioenzymatic assay for the release of histamine, upon immunologic 
and nonimmunologic stimulation. Human lung parenchyma were passively sen- 
sitized with serum from timothy-positive allergic patients  (radioallergosorbent 
test,  30-40%)  and challenged with 0.5  /~g/ml of timothy allergen. Analysis of 
the incubation media showed the presence of LTB4,  LTC4,  LTD4,  LTE4, and 
histamine. Maximum release of LTB4 and LTD4 was observed after 15  min of 
challenge (92.8  +  21,  and  67.8  ±  14  pmol/g tissue  wet weight,  respectively; 
mean ±  SEM) whereas maximum release of LTC4 was observed after 5 min of 
challenge (25 ±  7.1  pmol). In parallel to leukotriene formation, histamine was 
released rapidly and reached a  maximum after ~15  min of challenge (2.85  ± 
0.76 nmol/g tissue). 
When fragments of human lung parenchyma were stimulated with ionophore 
A23187  (4  ~M),  we  observed a  profile  of leukotriene and  histamine  release 
similar to that seen in response to the allergen. Ionophore A23187  stimulated 
the release of two- to  fivefold greater amounts of leukotrienes and histamine 
than did the allergen. Release of LTC4 and histamine was maximal after 5 min 
of stimulation (83 ±  22.2 and 5.2 ±  0.95  nmol/g tissue, respectively), whereas 
LTB4 and LTD4 release reached a maximum after 15 min (438 ±  66.6 and 205 
±  68 nmol/g tissue, respectively). In addition, human lung parenchyma metab- 
olized LTB4 into w-OH-LTB4 and w-COOH-LTB4. This tissue also released 5- 
bydroxy-eicosatetraenoic acid (5-Hete), 12-Hete, and 15-Hete. 
Fragments of human lung bronchi also released a similar profile of leukotrienes 
(except LTC4) and histamine when challenged with the allergen or ionophore 
A23187. Maximum release of LTB4 and LTD4 by allergen or ionophore stimu- 
lation  was  observed  after  -15  rain  (40  ±  7.5  and  21  ±  8  pmol/g  tissue, 
respectively, upon allergen challenge;  100  ±  13 and 47  ±  10.6 pmol/g tissue, 
respectively, upon ionophore stimulation).  The maximum release of histamine 
by bronchi  was  observed after  ~15  rain  of allergen  challenge and  5  rain  of 
ionophore stimulation (2.25 ±  0.65 and 3.15 ±  0.9 nmol/g tissue, respectively). 
The release of leukotrienes but not of histamine by human lung parenchyma 
upon both allergen and ionopbore challenge was inhibited by nordihydroguaiar- 
etic acid (NDGA) (IDa0, 2 ×  10 -6 M). Aspirin neither significantly inhibited nor 
stimulated the release of leukotrienes or histamine by this tissue. Sodium crom- 
oglycate  did  not  inhibit  the  release  of either  leukotrienes  or  histamine  by 
ionophore-stimulated parenchyma. However, at 10 -4 M, it slightly decreased the SALARI  ET  AL.  1913 
formation of leukotrienes  (20-56%,  P  <  0.05)  and  release of histamine  (50  + 
6%, P  <  0.05) by allergen-challenged human lung parenchyma. These observa- 
tions  indicate  that  human  lung  parenchyma  and  bronchi  release  significant 
amounts of leukotrienes and histamine upon allergen or ionophore stimulation. 
We wish to thank Dr. Nichola Barden for helpful advice, discussions, and critical comments 
on the manuscript. 
Received for publication  21 May 1985 and in revised form 21 August 1985. 
References 
1.  Goetzel, E.J. 1980. Mediators of immediate hypersensitivity derived from arachidonic 
acid. N. Engl. J. Med.  303:822. 
2.  Ts'ao, C., W.J. Metzger, R. Patterson, and I. M. Suszko. 1976. Histamine-containing 
cells in  bronchial  lavage fluid.  I.  Ultrastructural  characterization  and comparison 
with mast cells in three types of tissues of rhesus monkeys. Int, Arch.  Allergy Appl. 
lmmunol. 52:315. 
3.  Schild, H. O., D. F. Hawkins, J. L. Mongar, and H. Herxheimer. 1951. Reactions of 
isolated human asthmatic lung and bronchial tissue to a specific antigen.  Histamine 
release and muscular contractions. Lancet 2:376. 
4.  Murphy, R. C., S. Hammarstrom, and B. Samuelsson.  1979.  Leukotriene C, a slow 
reacting substance (SRS) from murine mastocytoma cells. Proc. Natl. Acad. Sci. USA. 
79:4275. 
5.  Morris, H. R., G. W. Taylor, P.J. Piper, M. N. Samhoun, andJ. R. Tippens. 1980. 
Slow reacting substances (SRSs): the structure identification of SRSs from rat baso- 
philic leukaemia cells. Prostaglandins.  19:185. 
6.  Borgeat, P., and B. Samuelsson.  1979. Transformation ofarachidonic acid by rabbit 
polymorphonuclear leukocytes.J. Biol. Chem. 254:2643. 
7.  Borgeat, P., and B.  Samuelsson.  1979.  Metabolism of arachidonic acid in polymor- 
phonuclear leukocytes.J. Biol. Chem. 154:7865. 
8.  Drazen, J. M., K. F. Austen, R. A. Lewis, D. A. Clark, G. Goto, A. Marfat, and E. J. 
Corey. 1980. Comparative airway and vascular activities of leukotriene C-1 and D in 
vivo and in vitro. Proc. Natl. Acad. Sci. USA. 77:4354. 
9.  Hanna, C. J., M.  K. Bach, P. D. Pare, and R. R. Schellenberg.  1981.  Slow-reacting 
substances  (leukotrienes)  contract  human  airway and  pulmonary vascular smooth 
muscle in vitro. Nature (Lond.).  290:343. 
10.  Dahl6n, S. E., P. Hedqvist, S. Hammarstrom, and B. Samuelsson. 1980. Leukotrienes 
are potent constrictors of human bronchi. Nature (Lond.) 288:484. 
11.  Weiss, J. W., J. M. Drazen, N. Coles, E. R. McFadden, Jr., P. F. Weller, E.J. Corey, 
R. A. Lewis, and K. F. Austen.  1982. Bronchoconstrictor effects of leukotriene C in 
humans. Science (Wash. DC). 216:196. 
12.  Holroyde, M. C., R. E. C. Altounyan, M.  Cole, M.  Dixon, and E. V. Elliott.  1981. 
Bronchoconstriction produced in man by leukotrienes C and D. Lancet. 2:17. 
13.  Griffin, M.,J. W. Weiss, A. G. Leitch, E. R. McFadden,Jr., E.J. Corey, K. F. Austen, 
and J. M. Drazen. 1983. Effects of leukotriene D on the airways in asthma. N. Engl. 
J. Med.  308:436. 
14.  Johnson, H. G., and M.  L. McNee.  1983. Secretogogue responses of leukotriene C4 
and D4: comparison of potency in canine trachea in vivo. Prostaglandins.  25:237. 
15.  Marom, Z.,J. H. Shelhamer, M. K. Bach, D. R. Morton, and M. Kaliner. 1981. Slow 
reacting  substances,  leukotrienes  C4  and  D4,  increase  the  release  of mucus  from 
human airways in vitro. Am. Rev. Respir. Dis. 126:449. 1914  LEUKOTRIENES  AND  HISTAMINE IN  HUMAN  LUNG 
16.  Coles, S. J., K. H. Neill,  L.  M.  Reid,  K. F.  Austen, Y.  Nil, E. J.  Corey, and  R. A. 
Lewis. 1983. Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion 
by human bronchial mucosa. Prostaglandins.  25:155. 
17.  O'Flaherty, J. T., M.J. Thomas, S. L. Cousart, W. L. Salzer, and C. E. McCall.  1982. 
Neutropenia induced by systemic infusion of 5,12-dihydroxy-6,8,10,14-eicosatetrae- 
noic acid.J.  Clin. Invest.  69:993. 
18.  Ford-Hutchinson, A. W., M. A. Bray, M. V. Doig, M. E. Shipley, and M.J.H. Smith. 
1981.  Leukotriene  B,  a  potent  chemokinetic and  aggregating substance  released 
from polymorphonuclear leukocytes. Nature (Lond.). 286:264. 
19.  Samuelsson, B.  1982.  The leukotrienes: an introduction. Adv. Prostaglandin Throm- 
boxane Leukotriene Res.  9:1. 
20.  Peters, S. P., D. W. MacGlashan, Jr., E. S. Schulman, R. P. Schleimer, E. C. Hayes, 
J.  Rokach,  N.  F.  Adkinson, Jr.,  and  L.  M.  Lichtenstein.  1984.  Arachidonic  acid 
metabolism in purified human lung mast cells. J. lmmunol.  132:1972. 
21.  Fels, A. O. S., N. A. Pawlowski, E. B. Cramer, T. K. C. King, Z. A. Cohn, and W. A. 
Scott.  1982. Human alveolar macrophages produce leukotriene B4. Proc. Natl. Acad. 
Sci. USA.  79:7866. 
22.  Verburg, K. M., R. R. Bowsher, and D. P. Henry. 1983. A new radioenzymatic assay 
for histamine using purified histamine N-methyl transferase. Life Sci. 32:2855. 
23.  Powell, W. S.  1980.  Rapid extraction of oxygenated metabolites of arachidonic acid 
from biological samples using octadecylsilyl silica. Prostaglandins.  20:947. 
24.  Borgeat, P., B. Fruteau de Laclos, H. Rabinovitch, S. Picard, P. Braquet, J. H~bert, 
and  M.  Laviolette.  1984.  Generation and structure  of the  lipoxygenase products: 
eosinophil-rich human polymorphonuclear leukocyte preparations characteristically 
release  leukotriene  C4  on  ionophore  A23187  challenge. J.  Allergy  Clin.  Immunol. 
74:310. 
25.  Borgeat, P., and B. Samuelsson. 1979. Transformation of arachidonic acid by rabbit 
polymorphonuclear leukocytes.J. Biol.  Chem.  254:2643. 
26.  Borgeat, P., S. Picard, P. Vallerand, and P. Sirois.  1981.  Transformation of arachi- 
donic  acid  in  leukocytes.  Isolation  and  structural  analysis  of a  novel  dihydroxy 
derivative. Prostaglandins Med.  6:557. 
27.  Sirois,  P.,  S.  Roy, J.  P.  T~trault,  P.  Borgeat,  S.  Picard,  and  E. J.  Corey.  1981. 
Pharmacological activity of leukotrienes A4, B4,  C4 and D4 on selected guinea pig, 
rat, rabbit and human smooth muscles. Prostaglandins Med. 7:327. 
28.  Hansson, G., T.  Bjorck, S.  E.  Dahl~n,  P.  Hedqvist, E.  Granstrom, and B.  Dahl~n. 
1983. Specific allergen induces contraction of bronchi and formation of leukotrienes 
C4, D4 and E4 in human asthmatic lung. Adv. Prostaglandin Thromboxane Leukotriene 
Res.  12:153. 
29.  Zijlstra, F., andJ. E. Vincent. 1984. Determination ofleukotrienes and prostaglandins 
in  [~4C]arachidonic  acid  labelled  human  lung  tissue  by  high-performance  liquid 
chromatography and radioimmunoassay. J. Chromatogr.  311:39. 
30.  Smith, M.J.H., A. W. Ford-Hutchinson, and M. A. Bray. Leukotriene B: a potential 
mediator of inflammation. J. Pharm. Pharmacol.  32:517. 
31.  Dahl~n, S. E., J. Bjork, P.  Hedqvist, K. E. Arfors, S. Hammarstrom, J. A. Lindgren, 
and  B.  Samuelsson.  1981.  Leukotrienes  promote  plasma  leakage  and  leukocyte 
adhesion in post capillary venules: in vivo effects with relevance to the acute inflam- 
matory response. Proc. Natl. Acad. Sci. USA.  78:3887. 
32.  Hansson, G., J. A.  Lindgren, S.  E.  Dahl~n,  P.  Hedqvist, and B. Samuelsson.  1981. 
Identification and biological activity of novel omega-oxidized metabolites of leuko- 
triene B4 from human leukocytes. FEBS (Fed. Eur. Biochem.  Soc.)Lett.  130:107. 
33.  Jubiz, W., O. Rodmark, C. Malmsten, G. Hansson, J. A. Lindgren, J. Palmblad, A. SALARI  ET  AL.  1915 
M. Ud6n, and B. Samuelsson. 1982. A novel leukotriene produced by stimulation of 
leukocytes with formyl methionylleucyl phenylalanine. J. Biol. Chem.  257:6106. 
34.  Camp, R. D. R., P. M. Woolard, A. I. Mallet, N.J. Fincham, A. W. Ford-Hutchinson, 
and  M.  A.  Bray.  1982.  Neutrophil  aggregating and  chemokinetic properties of a 
5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid isolated from human leukocytes. 
Prostaglandin.  23:631. 
35.  Ford-Hutchinson,  A.  W.,  Z.  Rackham, R.  Zamboni, J.  Rokach, and S.  Roy.  1983. 
Comparative biological activities of synthetic leukotriene B4 and its omega-oxidation 
products. Prostaglandins.  25:29. 
36.  Lewis,  R.  A., J.  M.  Drazen,  E. J.  Corey, and  K.  F.  Austen.  1981.  Structural  and 
functional characteristics of the leukotrienes. In SRS-A and Leukotrienes. P.J. Piper, 
editor. John Wiley & Sons, New York.  101-117. 
37.  Piper, P.J., M.  N. Samhoun, J. R. Tippins, T.J. Williams, M. A. Palmer, and M.J. 
Peck.  1981.  Pharmacological studies on pure SRS-A and synthetic leukotrienes C4 
and  D4. In  SRS-A and  Leukotrienes.  P.J.  Piper,  editor. John Wiley & Sons,  New 
York. 81-99. 
38.  Stenson,  W.  F.,  C.  W.  Parker,  and  T. J.  Sullinan.  1980.  Augmentation  of IgE- 
mediated release of histamine by 5-hydroxyeicosatetraenoic acid and  12-hydroxyei- 
cosatetraenoic acid. Biochem.  Biophys.  Res.  Commun. 96:1045. 
39.  Peters, S. P., M.  I. Siegel, A. Kagey-Sobotka, and L. M. Lichtenstein.  1981. Lipoxy- 
genase  products  modulate  histamine  release  in  human  basophils. Nature  (Lond.). 
292:455. 
40.  Peters,  S.  P.,  A.  Kagey-Sobotka, D.  W.  MacGlashan, Jr.,  M. J.  Siegel,  and  L.  M. 
Lichtenstein. 1982. The modulation of human basophil histamine release by products 
of 5-1ipoxygenase pathway.J. Immunol.  129:797. 
41.  Salari, H., P. Braquet, and P.  Borgeat.  1984. Comparative effects of indomethacin, 
acetylenic acids,  15-HETE, nordihydroguaiaretic acid and BW755C on the metabo- 
lism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukotrienes 
Med.  13:53. 
42.  Pepys, J., R.J. Davies, A. B. X. Breslin, D. J. Hendrick, and B.J. Hutchcroft. 1974. 
The effects of inhaled beclomethasone dipropionate (Becotide) and sodium cromo- 
glycate on asthmatic reactions to provocation tests. Clin. Allergy. 4:13. 
43.  Godfrey, S., and P. Konig. 1976. Inhibition of exercise-induced asthma by different 
pharmacological pathways. Thorax.  31 : 137. 
44.  Patel,  K.  R.  1981.  Calcium  antagonists  in  exercise-induced  asthma.  Br.  Med.  J. 
282:932. 
45.  Craps,  L.  1981.  Ketotifen  in  the  oral  prophylaxis of bronchial  asthma:  a  review. 
Pharmatherapeutica.  3:18. 
46.  Kaliner,  M.  A., J.  Belnnerhasset,  and  K.  F.  Austen.  1976.  Bronchial  asthma.  In 
Textbook of Immunopathology. P. A. Meischer and H.J. Muller-Eberhard, editors. 
Grune & Stratton, Inc., New York. 387-401. 